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2TRANSLATIONAL RELEVANCE
Pancreatic ductal adenocarcinoma is a leading cause of cancer death and has the lowest
survival rate for any solid cancer. Biomarkers for the early detection of pancreatic cancer are
urgently needed to improve survival, although studies assessing biomarkers for early detection
rarely use samples from patients with pre-clinical disease. For the first time, serum markers
CA19-9, CA125, CEACAM1 and REG3A have been assessed in samples taken up to 6 years
prior to clinical presentation of pancreatic cancer. We show that CA19-9 and CA125 are
elevated many months prior to clinical presentation of pancreatic cancer and when used in
combination, CA125 improved upon the performance of CA19-9 alone through the detection of
CA19-9 negative cases. Moreover, both markers can be used as prognostic tools in pancreatic
cancer. These markers have the potential, when combined, for screening high-risk groups,
particularly if used longitudinally.
3ABSTRACT
Purpose Biomarkers for the early detection of pancreatic cancer are urgently needed. The
primary objective of this study was to evaluate whether increased levels of serum CA19-9,
CA125, CEACAM1 and REG3A are present prior to clinical presentation of pancreatic cancer
and to assess the performance of combined markers for early detection and prognosis.
Experimental Design This nested case control study within UKCTOCS included 118 single-
and 143 serial-serum samples from 154 post-menopausal women who were subsequently
diagnosed with pancreatic cancer and 304 matched non-cancer controls. Samples were split
randomly into independent training and test sets. CA19-9, CA125, CEACAM1 and REG3A were
measured using ELISA and/or CLIA. Performance of markers to detect cancers at different
times prior to diagnosis and for prognosis was evaluated.
Results At 95% specificity, CA19-9 (>37 U/mL) had a sensitivity of 68% up to 1 year, and 53%
up to 2 yrs before diagnosis. Combining CA19-9 and CA125 improved sensitivity as CA125 was
elevated (>30 U/mL) in ~20% of CA19-9-negative cases. CEACAM1 and REG3A were late
markers adding little in combined models. Average lead times of 20-23 months were estimated
for test-positive cases. Pre-diagnostic levels of CA19-9 and CA125 were associated with poor
overall survival (HR 2.69 and 3.15, respectively).
Conclusions CA19-9 and CA125 have encouraging sensitivity for detecting pre-clinical
pancreatic cancer and both markers can be used as prognostic tools. This work challenges the
prevailing view that CA19-9 is up-regulated late in the course of pancreatic cancer
development.
4INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death and has the
lowest survival rate for any solid cancer (~2%) (1, 2). Surgical resection is the only chance of
cure, but due to advanced stage at presentation only 20% of patients have resectable tumours
(3). Of these, only 15% will have early-stage cancers (4, 5). When resection is possible followed
by adjuvant therapy, the 5-year survival is better at 20-30% (6). It is clear that early detection of
smaller tumors is necessary to improve resectability rates and survival. Indeed it was shown
that if tumor size at detection can be reduced from 3 to 2 cm, then there is an increase in
resectability from 7% to 83% with increased median survival from 7.6 to 17.2 months (7).
The serum marker CA19-9 (8-10) is the only biomarker used routinely in the management of
PDAC. It has a 79-81% sensitivity and 82-90% specificity for diagnosis (11), with false-positive
results observed in benign pancreatico-biliary diseases such as pancreatitis, cholangitis and
obstructive jaundice (12-14). Furthermore, CA19-9 is not expressed in 8-10% of the Caucasian
population with the Lewis a-b- genotype, as the CA19-9 epitope is the sialylated Lewis A blood
group antigen (14, 15). Despite this, CA19-9 has proved useful for disease management, where
increased post-therapy levels indicate poor prognosis and poor therapy response (16, 17).
Moreover, the levels of CA19-9 in the months and years prior to PDAC diagnosis have not
previously been examined, leaving its capacity to contribute to early diagnosis untested. Other
reported non-invasive diagnostic and/or prognostic markers of pancreatic cancer that have been
tested alone or in combination, include CA125 (18-21), CEA (22), CEACAM1 (23), MUC1 (24),
OPN/SPP1 (25), MIC1/GDF15 (26), REG3A/PAP1 (27, 28) and PKM2 (29). As yet, the clinical
utility of these markers remains to be determined and most require further multi-centre
validation.
A major shortcoming of cancer biomarker studies aiming to address early detection is a lack
of appropriate samples. Biomarkers tested in samples taken from patients diagnosed with
cancer and benign or healthy controls only address potential use for differential diagnosis.
Samples collected prior to diagnosis are preferential, enabling early changes to be detected,
with consistently rising levels in the lead up to diagnosis adding confidence to the discovery.
5The serum samples used in this study come from a repository collected as part of the UK
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS); a randomized controlled trial of
ovarian cancer assessing impact of screening on mortality using transvaginal ultrasound and
serum CA125 interpreted using the Risk of Ovarian Cancer Algorithm (ROCA). Preclinical
samples from participating women who subsequently developed PDAC were available for
evaluating CA19-9, CA125, CEACAM1 and REG3A for early diagnosis.
MATERIALS AND METHODS
Serum samples
This nested case control study was approved by the Joint UCL/UCLH Research Ethics
Committee A (Ref. 05/Q0505/57). Written informed consent was obtained from donors and no
data allowing identification of patients was provided. The study set comprised serum from
women recruited to UKCTOCS between 2001 and 2005 and collected according to a SOP (30,
31). Trial participants at enrolment were post-menopausal women aged 50-74 who had no
family history of ovarian cancer. All participants were ‘flagged’ with the national agencies for
cancer registrations and deaths using their NHS number. Women subsequently diagnosed with
pancreatic cancer (cases) were identified by cross-referencing with the Health and Social Care
Information Centre cancer registry codes and death codes (ICD10 C25.0/1/2/3/9). Initially, 171
cases were identified (with 304 associated samples) that had not been registered as having any
other cancer since randomization. Matched non-cancer controls (i.e. with no cancer registry
code) from individual women (1 per case sample; n=304) were selected based on collection
date and center to minimize variation due to handling. For the 171 cases, confirmation of
diagnosis was sought from GPs and consultants through questionnaire and from the Hospitals
Episode Statistics database. As a result, 17 cases were excluded that did not have a confirmed
diagnosis of pancreatic ductal adenocarcinoma. The resulting study set was 261 serum
samples from 154 women subsequently diagnosed with pancreatic ductal adenocarcinoma up
to 6.5 years later and 304 matched control sera from 304 women. 119 cases provided single
6samples and 35 provided 2 or more serial samples. Table 1 shows clinical, lifestyle and sample
data for the study set. Samples were distributed randomly into discovery and validation sets and
grouped by time to diagnosis as indicated in Table 2.
Serum measurements
All serum tests were executed and interpreted by trained and experienced staff. Samples were
randomized for testing and blinded to the experimenters prior to interpretation. CA19-9 was
measured in discovery set samples using the Mucin PC/CA19-9 ELISA kit (Alpha Diagnostic
International) according to the manufacturer, using a 1:4 serum dilution. Values lower than the
assay’s limit of detection were given a ‘low’ value of 0.6 U/mL. Duplicate measurements gave
an average CV of 6.9% (R2=0.998). CA19-9 was measured in validation set samples using the
Cobas CA19-9 CLIA with a CA19-9 Calibrator Set (Roche and Fujirebio Diagnostics), run on a
Cobas E411 analyzer with PreciControl Tumour Marker to monitor assay imprecision. The
average CV from 31 replicate measurements of serum standard run at the same time was
3.2%.
CA125 was measured using the Cobas CA125 II CLIA with a CA125 II Calibrator Set (Roche
and Fujirebio Diagnostics) on a Cobas E411 analyzer with PreciControl Tumour Marker, as
above. Assays were performed originally on 320 fresh study samples in UKCTOCS and on
discovery set samples (after two freeze thaw cycles) where original values were missing.
Assays were repeated on all validation set samples. For matched duplicate readings, average
CV was 8.5 % (R2=0.997). The average CV from 31 replicate measurements of serum standard
was 4.1%.
For CEACAM1, a sandwich ELISA was established using the human CEACAM1/CD66a
DuoSet kit (R&D Systems), as described in Supplementary Data. Replicate readings gave an
average CV of 10.3%; (R2=0.81). Serum REG3A/PAP was measured using the PANCREPAP
ELISA kit (DynaBio) according to the manufacturer, using a 1:100 serum dilution. Replicate
readings gave an average CV of 21.9 % (R2=0.46).
7Statistical Analysis
GraphPad Prism and MedCalc software were used for statistical analyses. For normally
distributed data, the Student t test was used to assess significance of differences, otherwise the
Mann-Whitney U-test was used. Fisher’s exact test was used to assess significance of
associations for non-continuous variables. Correlation analysis used Spearman’s rank test. All P
values <0.05 were considered significant. Receiver operating characteristic (ROC) curves were
constructed for each marker and combinations to assess diagnostic accuracy. Kaplan-Meier
analysis was used to examine biomarker levels in relation to survival using time from sample
collection to death.
RESULTS
Study set characteristics
There was no significant difference in time to centrifugation between case control samples,
whilst there was a difference in mean age (2.8 years; P<0.0001) and BMI (1 kg/m2; P=0.041)
between cases and controls (Table 1). Hormone replacement therapy (HRT) use at
randomization was associated with lowered risk of pancreatic cancer (OR=0.49; 95%CI 0.27-
0.88; P=0.022), whilst oral contraceptive pill use had no association. Smoking was not
associated with pancreatic cancer, whilst alcohol consumption was negatively associated
(OR=0.4; P=0.01). Notably, response rate for reporting smoking and alcohol consumption was
poor, particularly from those volunteers who developed cancer. The death rate was 95.5% for
cases with a median time from diagnosis to death of 4 months.
Serum CA19-9, CA125, CEACAM1 and REG3A in discovery set
CA19-9, CEACAM1 and REG3A were measured in all discovery samples using commercial
ELISA kits, whilst CA125 was measured using a robust CLIA assay. There was a significant
increase in level between all case and control samples for CA19-9 (P<0.0001) and CA125
(P=0.0004), but not for CEACAM1 or REG3A (Figure 1). Time to diagnosis plots showed
8increasing CA19-9 and CA125 for cases in the lead up to diagnosis, whereas CEACAM1 and
REG3A showed no such trend (Supplementary Data; Figure S1). For serial samples from the
same women, CA19-9 and CA125 increased towards diagnosis in the majority of cases
(Supplementary Data; Figure S2), whereas none showed increasing CEACAM1 or REG3A.
Markers were analyzed according to time to diagnosis (grouped as 0-0.5 yrs, 0.5-1 yrs, 1-2
yrs, 2-3, yrs, 3+ yrs, 0-4+ yrs (all samples), 0-1 yrs and 1-4 yrs). In cases where serum was
obtained <12 months before diagnosis, median CA19-9 was 43.2 U/mL (IQR 5.7-136.2 U/mL)
compared to 3.1 U/mL (IQR 0.6-6.9 U/mL) in controls (P<0.0001; AUC=0.82) (Figure 2). For
CA125, median values were 24.1 U/mL (IQR 12.9-47.9) for cases and 12.8 U/mL (IQR 9.3-14.5)
for controls (P<0.0001; AUC=0.78). CEACAM1 (P=0.045; AUC=0.71) and REG3A (P=0.022;
AUC=0.73) were only significantly elevated in the 6 months before diagnosis. CA19-9 and
CA125 were also raised in the 0.5-1 year pre-diagnosis group (P=0.0016; AUC=0.80 and
P=0.0167; AUC=0.73, respectively), but not >1 year. There were no significant associations for
any of the markers with respect to time to centrifugation, age, BMI, smoking, alcohol
consumption, HRT or OCP use, except REG3A, which correlated with age (=0.31; P<0.001) in
the controls.
Sensitivities for detection of PDAC were calculated using selected cut-offs (Table 3). CA19-9
(>25 U/mL) was the best performing marker, discriminating cases from controls with SN/SP of
70.6%/95.0% and 64.7/95.5% in the 0-0.5 yrs and 0.5-1 yrs prior to diagnosis (Table 3). The
SN/SP for detection of PDAC with CA125 (>20 U/mL) in these time periods were somewhat
poorer at 70.6%/90.0% and 52.9%/86.4%, respectively. CEACAM1 and REG3A were poor at
detecting cancer compared to CA19-9 or CA125; for the 0-0.5 yrs group, the SN/SP for
CEACAM1 was 53.3/83.3% (>50 ng/mL), whilst for REG3A it was 29.4/90% (>13 ng/mL).
Combining markers showed the model ‘CA19-9>37 U/mL or CA125>30 U/mL’ provided the
highest sensitivities at >90% specificity; 57.1% for the 0-1 year group (PPV 90.9%; OR=26.67,
95%CI 5.6-128.2) and 44.2% for the 0-2 year time group (PPV 92.0%; OR=24.59, 95%CI 5.4-
111.4), but were only marginally better (and not significantly so) than using CA19-9 alone (Table
93). Adding CEACAM1 and/or REG3A into models decreased specificity with little improvement
in sensitivity (data not shown). Logistic regression showed the best combined model (CA19-9,
CA125 and CEACAM1) had an AUC of 0.88 (SE=0.042; 95%CI 0.79-0.95) for the 0-1 year
group, but was not significantly higher than using CA19-9 alone (AUC=0.82). Together, these
data indicate that CA19-9, and possibly CA125, may be useful in predicting PDAC up to 24
months in advance of diagnosis.
Validation of CA19-9 and CA125 as early detection biomarkers
CA19-9 and CA125 were further assessed in a validation set comprising 168 samples from 101
cases. This was subsequently restricted to 138 samples by removing all but one serial samples
(at random) from the same case/woman that fell within the same time group (Table 2). In this
restricted set, CA19-9 was significantly higher in cases than controls for the 0-0.5, 1-2, 2-3 and
3+ year time groups, though failed significance for the 0.5-1 year group (Supplementary Data
Figure S3). CA125 was significant for the 0-0.5 and 3+ year time groups. The simple cut-off
model ‘CA19-9>37 U/mL or CA125>30 U/mL’ applied to this dataset gave 56.7% sensitivity and
90.6% specificity for the 0-1 year group (PPV=77.3%; OR=12.55, 95%CI 3.89-40.48), compared
to 50% sensitivity and 94.3% specificity using CA19-9 alone (PPV=83.3%; OR=16.67, 95%CI
4.25-65.43) (Table 4). For the 0-2 year group, sensitivity was 40.6% and specificity 90.5%
(PPV=74.3%; OR=6.54, 95%CI 2.80-15.28). Logistic regression combining CA19-9 and CA125
gave AUCs of 0.90 and 0.76 for the 0-0.5 and 0-1 year groups, respectively, but was not
significantly higher than using CA19-9 alone. Thus, CA125 adds little discriminatory power in
combined models. Despite this, 13 out of 53 positive cases in the validation set were detected
solely using CA125.
Our intention was also to build algorithms based on available serial/longitudinal data. ROCA
used in UKCTOCS (32, 33) could not be developed for CA19-9 due to lack of serial control
samples. A Parametric Empirical Bayes algorithm (34) applied to the combined dataset gave
sensitivities of 19% and 17% (at 95% specificity) for CA19-9 and CA125, respectively, and was
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thus poorer than the threshold models. This again is likely due to an insufficient longitudinal
data for accurate model building.
Lead time estimation
In two cases with sufficient longitudinal samples, increasing CA19-9 was apparent as early as 3
years prior to diagnosis of PDAC (Supplementary Data; Figure S2; Cases 5 and 6). However,
most marker ‘change-points’ occurred within 12 months of diagnosis. CA125 tended to rise later
than CA19-9, but was diagnostic alone in ~20% of cases where CA19-9 was not elevated
(Figure S2; Case 40). Taking the earliest point of detection for cases with longitudinal samples,
the model ‘CA19-9>30 or CA125>25’ gave an average lead time of 22.9 months (median 18.5
months; IQR 8.0-32.8 months). Whilst estimated lead times were slightly higher for combined
models versus CA19-9 alone, differences were not significant.
Prognosis
The four markers were investigated as prognostic factors using time from sample collection to
death in cases where pancreatic cancer was cited as the primary or contributory cause of death.
Firstly, poor and good prognosis case samples were respectively defined as falling below and
above the median time from sample collection to death (30.5 months). Both CA19-9 and CA125
were significantly elevated in the poor prognosis group, whilst CEACAM1 and REG3A were not
(data not shown). Kaplan-Meier analysis confirmed a significant difference in survival curves for
CA19-9 (cut-off 40 U/mL; Log-rank test P<0.0001; HR=2.69, 95%CI 1.84-3.91) and CA125 (cut-
off 25 U/mL; Log-rank test P<0.0001; HR= 3.15, 95%CI 2.11-4.69), confirming them as
prognostic markers (Figure 3). Median survival times from collection were 14.5 versus 36.0
months for CA19-9 and 14.0 versus 35.0 months for CA125.
DISCUSSION
To our knowledge this is the first study to show serum CA19-9, CA125, CEACAM1 and REG3A
are significantly elevated prior to PDAC diagnosis. To our surprise, in 16% of cases, CA19-9
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was elevated (>37 U/mL) 2-3 years before diagnosis, with sensitivity increasing towards
diagnosis. The PPV of CA19-9 was 90% up to 1 year before diagnosis and >80% up to 2 years,
depending on the cut-off level used. CA125 also increased in pre-clinical disease and although
combined models gave only modest increases in performance versus CA19-9 alone, CA125
detected 13% of CA19-9-negative cases; some of which are likely to be Lewis antigen negative.
Notably, combined models gave average lead times up to 23 months. Together, our data
support the notion that a panel of markers including CA19-9 may be beneficial for earlier
detection of pancreatic cancer with potential use in screening.
Three studies have explored the utility of serum CA19-9 levels as a screening tool for
pancreatic cancer (35-37). Kim et al assessed CA19-9 in 70,940 asymptomatic individuals
identifying 4 cancers among 1,063 individuals with elevated CA19-9 (>37 U/mL; PPV= 0.9%;
sensitivity 100%; specificity 98.5%). Notably, a higher proportion of women (2.5%) compared to
men (0.5%) had elevated CA19-9. This did not increase with age in women, as was observed
here. Given the low predictive value of CA19-9 and low prevalence of pancreatic cancer in the
general population, it was concluded from these studies that CA19-9 testing alone has no utility
as a screening tool. However, here CA19-9 elevations were noted up to 36 months prior to
diagnosis, indicating its potential as a first line test for early detection that may increase the
number of patients with resectable disease. These results need to be independently validated.
Annual CA19-9 blood testing may also benefit high-risk populations such as those from kindred
with familial pancreatic cancer. Guidelines for the surveillance of these family members are not
established, although there are recent studies assessing outcomes of screening these high-risk
populations (38, 39).
Serum CA125 has been evaluated as a marker for detecting malignant versus benign
pancreatic tumours with a reported sensitivity of 60.8% and specificity of 83.3% (21). Combining
CA19-9 and CA125 gave values of 87.8% and 77.8% respectively, with the authors concluding
that test results should be interpreted in reference to imaging. A similar study reported a
sensitivity of 56.9% and specificity of 77.6%, with CA125 providing a limited contribution in
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jaundiced patients (40). Herein, in the pre-diagnosis setting, we show that CA125 performed
with higher specificity, providing additional sensitivity in combination with CA19-9.
CEACAM1 is expressed in pancreatic carcinoma in situ lesions, and thus has early stage
marker potential (23). It was further shown in this previous study that serum CEACAM1 had
superior accuracy to CA19-9 in clinical samples from PDAC patients. Whilst the function of
CEACAM1 remains unclear, several studies have identified its aberrant expression in a variety
of cancers often with conflicting reports (41-43). Herein, CEACAM1 appears to be up-regulated
in pancreatic adenocarcinoma, although is elevated in serum closer to diagnosis as compared
to CA19-9. CEACAM1 did not significantly improve classification in combined models and it was
not a prognostic factor. We conclude that serum CEACAM1 is not an early marker of pancreatic
cancer.
REG3A expression has been associated with pancreatic inflammation (44) and cancer (27,
28, 45). In the latter study, REG3A had 90% sensitivity and 82.8% specificity for discriminating
PDAC cases from healthy controls and was not correlated with CA19-9 level or associated with
concomitant pancreatitis or jaundice. In the present study, REG3A was discriminatory within 6
months of diagnosis, but was rarely elevated independently of CA19-9. In summary, REG3A is
a poor early marker, adding little in combined models.
Our data also confirm CA19-9 as a prognostic marker since we show that pre-diagnosis
cases with levels <40 U/mL had a prolonged median survival (from 14.5 to 36 months using
time from blood draw), and is in agreement with published data (reviewed in (11)). CA125 was
similar in predicting overall survival, and thus also appears to be a prognostic factor in
pancreatic cancer. This is supported by the notion that CA125 plays a direct role in the
progression and dissemination of pancreatic tumour cells (46).
Our study has several limitations. Firstly, only post-menopausal women were studied, and
hence may not reflect the utility of pancreatic tumor markers in the general population.
Secondly, there was insufficient information on grading, staging, tumor size and treatment to be
able to examine correlations with the markers. Indeed, it is likely that many of the test-positive
cases were at an advanced stage of disease when tested, in agreement with observed
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correlations between serum CA19-9 levels and pancreatic tumor burden (47); although this may
not always hold true (48). Thirdly, the number of cases (and controls) with serial samples was
insufficient to accurately build and assess longitudinal algorithms. Fourthly, there was a lack of
data on benign morbidities in both the case and control groups for which CA19-9 may be
elevated. Despite these limitations, the study is unique in that pre-clinical samples were
investigated, allowing an objective assessment of how serological markers change during
disease progression. Indeed, our findings suggest that raised CA19-9 can be detected early in
the course of PDAC development when tumor size is likely to be smaller and when survival
outcomes are improved (7). Importantly, although the majority of test positive cases in our study
had elevated CA19-9 (and/or CA125) within 1 year of diagnosis, likely indicating advanced
disease, these patients still went undiagnosed. This alludes to the non-specific nature of the
symptoms of pancreatic cancer, but also raises the possibility of an earlier diagnosis that may
improve outcome. Whilst one recent study has assessed pre-diagnostic PDAC samples (from
the prospective EPIC cohort), reporting that autoantibodies against ezrin appear early in PDAC
development, CA19-9 levels were unfortunately not reported in the 16 cases examined (49).
Our data also suggest that that HRT use at randomization was associated with lowered risk
of pancreatic cancer. The apparent protective effect of HRT use is at odds with two large
prospective cohort studies showing no association (50, 51). The reason for this discrepancy is
unclear, but may be a chance association given the much lower number of controls used in the
present study.
In conclusion, CA19-9 may have clinical utility in screening for pancreatic cancer as a first
line test, particularly if used longitudinally in higher risk or symptomatic populations, whilst
CA125 measurements may improve its performance and increase its prognostic value. It is
unclear whether the use of other screening investigations (EUS, CT scan) would have allowed
earlier diagnosis (i.e. at a still resectable state) when applied at the time of a CA19-9 or CA125
rise and this would need to be trialed in future studies.
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Table 1 Clinical, lifestyle and sample characteristics data for whole study set. aP values
determined using Mann Whitney or Fisher’s Exact test. BMI = body mass index at recruitment;
HRT = hormone replacement therapy; OCP = oral contraceptive pill; na = not applicable.
Variable Cases Controls P value
No. individuals 154 304
No. samples 261 304
Tumor site
tail 8 na
body 10 na
head 65 na
unspecified 71 na
Mean time to spin (hrs) (range) 21.8 (0.5-47) 22.0 (6.9-47) 0.62
Mean age at sample draw (yrs) (range) 65.3 (51.2-74.9) 62.5 (50.4-77.5) <0.0001
Mean BMI (kg/m2) (range) 27.6 (17.8-43.7) 26.6 (17.9-44.4) 0.041
Mean time from sample collection to diagnosis
(months) (range) 25.5 (0-79) na
HRT use (at randomisation)
yes 16 58 0.022
no 138 246 (OR 2.03)
OCP use (ever)
yes 79 163 0.69
no 75 141
Smoker
yes 15 75 1.00
no 28 136
no response 111 93
Alcohol
yes 25 182 0.01
no 20 58 (OR 2.5)
no response 109 64
Deaths as of 03/2013 (%) 95.45% 1.32%
Median time from diagnosis to death (months)
(range) 4.04 (1-45) na
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Table 2 Sample sets and case controls used in study. a In the ‘restricted’ validation set, serial
samples from the same woman falling in the same time group were removed at random to leave
a single representative sample. There were no such samples in the discovery set.
Time group
(yrs)
Total
case
samples
Total
control
samples
Discovery
case
samples
Discovery
control
samples
Validation
case
samples
(all)
Validation
case
samples
(limited)
Validation
control
samples
0-0.5 43 47 17 20 26 12 27
0.5-1 42 48 18 22 24 18 26
1-2 57 64 17 22 40 34 42
2-3 46 54 13 17 33 32 37
3-4 30 41 12 18 18 18 23
4+ 43 50 16 21 27 24 29
0-1 85 95 35 42 50 30 53
0-2 142 159 52 64 90 64 95
0-3 188 213 65 81 123 96 132
0-4+ 261 304 93 120 168 138 184
1-3 103 118 30 39 73 66 79
3+ 73 91 28 39 45 42 52
Total samples 261 304 93 120 168 138 184
Total cases 154 53 101 101
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Table 3 Performance of cut-off models for discovery set. Darker shading denotes higher values. See Supplementary Data; Table S1 for
numbers of test positive cases and controls for using the CA19-9 >37 U/mL and CA125 >30 U/mL models.
Time
group
Mean time
to Dx
(months) Parameter
CA19-9
>25
CA125
>20
CEACAM1
>50
REG3A
>13
CA125 or
CA19-9
CA19-9
>30
CA125
>25
CA125 or
CA19-9
CA19-9
>37
CA125
>30
CA125 or
CA19-9
CA19-9
>40
CA125
>25
CA125 or
CA19-9
0-0.5 yrs 2.94
Sensitivity 70.6 70.6 53.3 29.4 88.2 58.8 52.9 64.7 52.9 47.1 58.8 52.9 52.9 58.8
Specificity 95.0 90.0 83.3 90.0 85.0 95.0 100.0 95.0 100.0 100.0 100.0 100.0 100.0 100.0
0.5-1 yrs 9.11
Sensitivity 64.7 52.9 23.5 37.5 77.8 64.7 35.3 66.7 58.8 17.6 55.6 47.1 35.3 50.0
Specificity 95.5 86.4 81.0 90.9 81.8 95.5 90.9 86.4 95.5 95.5 90.9 95.5 90.9 86.4
1-2 yrs 18.24
Sensitivity 23.5 17.6 46.7 18.8 29.4 23.5 11.8 23.5 17.6 5.9 17.6 17.6 11.8 17.6
Specificity 100.0 86.4 55.0 90.5 86.4 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
2-3 yrs 28.76
Sensitivity 8.3 7.7 33.3 7.7 15.4 8.3 0.0 7.7 8.3 0.0 7.7 8.3 0.0 7.7
Specificity 88.2 94.1 68.8 94.1 82.4 88.2 100.0 88.2 94.1 100.0 94.1 94.1 100.0 94.1
3+ yrs 52.54
Sensitivity 10.7 8.0 28.6 21.4 14.3 3.6 8.0 10.7 3.6 4.0 7.1 3.6 8.0 10.7
Specificity 89.7 87.2 55.6 81.6 79.5 89.7 89.7 82.1 94.9 94.9 92.3 94.9 89.7 87.2
0-4+ (all) 25.44
Sensitivity 34.1 30.3 35.6 23.3 43.0 29.7 21.3 33.3 26.4 14.6 28.0 24.2 21.3 28.0
Specificity 93.3 88.3 66.7 88.1 82.5 93.3 95.0 89.2 96.7 97.5 95.0 96.7 95.0 92.5
0-1 yrs 6.11
Sensitivity 67.6 61.8 37.5 33.3 82.9 61.8 44.1 65.7 55.9 32.4 57.1 50.0 44.1 54.3
Specificity 95.2 88.1 82.1 90.5 83.3 95.2 95.2 90.5 97.6 97.6 95.2 97.6 95.2 92.9
0-2 yrs 12.18
Sensitivity 52.9 47.1 40.4 28.6 65.4 49.0 33.3 51.9 43.1 23.5 44.2 39.2 33.3 42.3
Specificity 96.9 87.5 72.9 90.5 84.4 96.9 96.9 93.8 98.4 98.4 96.9 98.4 96.9 95.3
1-4+ yrs 37.10
Sensitivity 14.0 10.9 34.5 17.5 19.0 10.5 7.3 13.8 8.8 3.6 10.3 8.8 7.3 12.1
Specificity 92.3 88.5 58.3 86.8 82.1 92.3 94.9 88.5 96.2 97.4 94.9 96.2 94.9 92.3
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Table 4 Performance of cut-off models for restricted validation set. Darker shading denotes higher values. See Supplementary Data; Table S1
for numbers of test positive cases and controls for using the CA19-9 >37 U/mL and CA125 >30 U/mL models.
Time group
Ave time to
Dx (months) Parameter
CA19-9
>25
CA125
>20
CA19-9
or CA125
CA19-9
>30
CA125
>25
CA19-9
or CA125
CA19-9
>37
CA125
>30
CA19-9 or
CA125
CA19-9
>40
CA125
>25
CA19-9 or
CA125
0-0.5 yr 3.42 Sensitivity 75.0 75.0 83.3
75.0 58.3 83.3 75.0 41.7 83.3 75.0 58.3 83.3
Specificity 77.8 77.8 63.0 85.2 92.6 85.2 92.6 96.3 88.9 100.0 92.6 92.6
0.5-1 yr 9.27 Sensitivity 24.0 24.0 22.0
43.8 13.3 50.0 37.5 12.5 43.8 31.3 13.3 37.5
Specificity 50.0 20.0 62.5 96.2 96.2 92.3 96.2 96.2 92.3 96.2 96.2 92.3
1-2 yr 18.68 Sensitivity 32.4 20.6 41.2
32.4 11.8 35.3 23.5 8.8 26.5 20.6 11.8 23.5
Specificity 85.7 78.6 69.0 92.9 97.6 90.5 92.9 97.6 90.5 95.2 97.6 92.9
2-3 yr 29.24 Sensitivity 34.4 25.0 50.0
28.1 18.8 43.8 18.8 15.6 31.3 18.8 18.8 34.4
Specificity 94.4 80.6 77.8 94.4 97.2 91.7 97.2 97.2 94.4 97.2 97.2 94.4
3+ yr 50.07 Sensitivity 23.8 35.7 45.2
14.3 14.3 26.2 9.5 7.1 14.3 9.5 14.3 21.4
Specificity 94.2 78.8 75.0 98.1 88.5 86.5 98.1 92.3 90.4 98.1 88.5 86.5
0-4+ (all) 25.13 Sensitivity 35.5 30.4 50.0
30.4 18.1 39.9 23.9 13.0 30.4 22.5 18.1 31.9
Specificity 89.6 80.9 73.8 94.0 94.0 89.1 95.6 95.6 91.3 97.3 94.0 91.3
0-1 yr 6.93 Sensitivity 56.7 40.0 66.7
53.3 30.0 60.0 50.0 23.3 56.7 46.7 30.0 53.3
Specificity 84.9 84.9 73.6 90.6 94.3 88.7 94.3 96.2 90.6 98.1 94.3 92.5
0-2 yr 13.17 Sensitivity 43.8 29.7 53.1
42.2 20.3 46.9 35.9 15.6 40.6 32.8 20.3 37.5
Specificity 85.3 82.1 71.6 91.6 95.8 89.5 93.7 96.8 90.5 96.8 95.8 92.6
1-4+ yr 34.02 Sensitivity 29.6 27.8 45.4
24.1 14.8 34.3 16.7 10.2 23.1 15.7 14.8 25.9
Specificity 91.5 79.2 73.8 95.4 93.8 89.2 96.2 95.4 91.5 96.9 93.8 90.8
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FIGURE LEGENDS
Figure 1 Box and whisker plots showing serum levels of CA19-9, CA125, CEACAM1 and
REG3A for all case and control discovery set samples. Whisker limits represent the 5th and 95th
percentiles, the box limits represent interquartile range, the horizontal line the median and the
cross the mean. Case and control groups were compared using the Mann-Whitney test; P
values are shown above the plots.
Figure 2 Box and whisker plots showing serum levels of CA19-9, CA125, CEACAM1 and
REG3A for case control discovery samples grouped into different time to diagnosis groups.
Whisker limits represent the 5th and 95th percentiles, the box limits represent interquartile range,
the horizontal line the median and the cross the mean. Case and control groups were compared
using the Mann-Whitney test; P values are shown above the plots.
Figure 3 Survival curves for CA19-9 and CA125 using time from sample collection to death due
to pancreatic cancer.
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Figure 3
Supplementary Data – O’Brien et al.
CEACAM1 ELISA
For serum CEACAM1 measurements, a sandwich ELISA was established using the
human CEACAM1/CD66a DuoSet kit (R&D Systems) as follows. Mouse anti-human
CEACAM1 monoclonal antibody was coated onto ELISA plates at 4 g/mL overnight
at room temperature (RT). Plates were washed 3 times in PBS containing 0.05%
Tween-20 and then wells were blocked with 1% BSA in dilution buffer (PBS) for 1 hr
at RT. After washing three times, 100 mL of diluted sample (1:50) was added as
duplicates with a standard dilution series (recombinant human CEACAM1; 23.4-6,000
pg/mL) and blanks. After incubation for 2 hrs at RT, plates were washed 3 times and
100 L of biotinylated goat anti-human CEACAM1 detection antibody (100 ng/mL)
was added and incubated for a further 2 hrs at RT. After 3 washes, streptavidin-HRP
was added and plates incubated for 20 min at RT. After a further 3 washes, 100 L of
a 1:1 mixture of H2O2 and tetramethylbenzidine was added and incubated for 20 min
at RT in the dark. Finally, 50 L of stop solution (2N H2SO4) was added and the
plates read in a blanked microtitre plate reader at 450 nm.
Time group Parameter CA19-9 >37 CA125 >30
CA125 or
CA19-9 CA19-9 >37 CA125 >30
CA125 or
CA19-9
Case positive 9 8 10 9 5 10
Case negative 8 9 7 3 7 2
Control positive 0 0 0 2 1 3
Control negative 20 20 20 25 26 24
Sensitivity 52.94 47.06 58.82 75.00 41.67 83.33
Specificity 100.00 100.00 100.00 92.59 96.30 88.89
No. cases 17 17 17 12 12 12
No. controls 20 20 20 27 27 27
Case positive 10 3 10 6 2 7
Case negative 7 14 8 10 14 9
Control positive 1 1 2 1 1 2
Control negative 21 21 20 25 25 24
Sensitivity 58.82 17.65 55.56 37.50 12.50 43.75
Specificity 95.45 95.45 90.91 96.15 96.15 92.31
No. cases 17 17 18 16 16 16
No. controls 22 22 22 26 26 26
Case positive 3 1 3 8 3 9
Case negative 14 16 14 26 31 25
Control positive 0 0 0 3 1 4
Control negative 22 22 22 39 41 38
Sensitivity 17.65 5.88 17.65 23.53 8.82 26.47
Specificity 100.00 100.00 100.00 92.86 97.62 90.48
No. cases 17 17 17 34 34 34
No. controls 22 22 22 42 42 42
Case positive 1 0 1 6 5 10
Case negative 11 13 12 26 27 22
Control positive 1 0 1 1 1 2
Control negative 16 17 16 35 35 34
Sensitivity 8.33 0.00 7.69 18.75 15.63 31.25
Specificity 94.12 100.00 94.12 97.22 97.22 94.44
No. cases 12 13 13 32 32 32
No. controls 17 17 17 36 36 36
Case positive 1 1 2 4 3 6
Case negative 27 24 26 38 39 36
Control positive 2 2 3 1 4 5
Control negative 37 37 36 51 48 47
Sensitivity 3.57 4.00 7.14 9.52 7.14 14.29
Specificity 94.87 94.87 92.31 98.08 92.31 90.38
No. cases 28 25 28 42 42 42
No. controls 39 39 39 52 52 52
Case positive 24 13 26 33 18 42
Case negative 67 76 67 105 120 96
Control positive 4 3 6 8 8 16
Control negative 116 117 114 175 175 167
Sensitivity 26.37 14.61 27.96 23.91 13.04 30.43
Specificity 96.67 97.50 95.00 95.63 95.63 91.26
No. cases 91 89 93 138 138 138
No. controls 120 120 120 183 183 183
Case positive 19 11 20 15 7 17
Case negative 15 23 15 15 23 13
Control positive 1 1 2 3 2 5
Control negative 41 41 40 50 51 48
Sensitivity 55.88 32.35 57.14 50.00 23.33 56.67
Specificity 97.62 97.62 95.24 94.34 96.23 90.57
No. cases 34 34 35 30 30 30
No. controls 42 42 42 53 53 53
Case positive 22 12 23 23 10 26
Case negative 29 39 29 41 54 38
Control positive 1 1 2 6 3 9
Control negative 63 63 62 89 92 86
Sensitivity 43.14 23.53 44.23 35.94 15.63 40.63
Specificity 98.44 98.44 96.88 93.68 96.84 90.53
No. cases 51 51 52 64 64 64
No. controls 64 64 64 95 95 95
Case positive 5 2 6 18 11 25
Case negative 52 53 52 90 97 83
Control positive 3 2 4 5 6 11
Control negative 75 76 74 125 124 119
Sensitivity 8.77 3.64 10.34 16.67 10.19 23.15
Specificity 96.15 97.44 94.87 96.15 95.38 91.54
No. cases 57 55 58 108 108 108
No. controls 78 78 78 130 130 130
Table S1 Numbers of test positive cases and controls using CA19-9 37 U/mL and CA125 30 U/mL cut-offs
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Figure S1 Scatter plots showing distribution of CA19-9, CA125,
CEACAM1 and REG3A levels against time to diagnosis for
discovery set. Zero represents the point of clinical diagnosis.
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Figure S2 Examples of CA19-9 and CA125 levels in individual cases with
serial/longitudinal samples.
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Figure S3 Box and whisker plots showing serum levels of CA19-9 and
CA125 for case control validation samples grouped into different time to
diagnosis groups. Whisker limits represent the 5th and 95th percentiles,
the box limits represent interquartile range, the horizontal line the median
and the cross the mean. Case and control groups were compared using the
Mann-Whitney test; significant P values (<0.05) are shown above the plots.
